May 20, 2024 07:17 AM EDT

Gilead's rare liver disease drug improves symptoms in another Phase 3 study ahead of FDA decision

Gilead reported more positive data over the weekend from its rare liver disease drug candidate seladelpar, which it got when it

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead­'s rare liv­er dis­ease drug im­proves symp­toms in an­oth­er Phase 3 study ahead of FDA de­ci­sion